Ipamorelin vs MK-677

Before anything else: the dataset lists Ipamorelin and MK-677 in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is recovery and sleep and muscle growth. On this site's goal weighting — an editorial priority score, not a measure of effect size — Ipamorelin rates 4/5 for recovery and sleep and MK-677 rates 5/5. Outside that overlap only MK-677 goes further, carrying weight for appetite control; Ipamorelin's declared goals stop at the overlap.

MK-677 sits one step firmer: controlled human trials behind it, without an approval — never approved, and trials flagged higher fasting glucose. Ipamorelin has some human data, but it is small, old, or uncontrolled — small early-phase work only; development was discontinued. One tier is a real difference but not a decisive one; it should not on its own settle the choice.

Ipamorelin is a subcutaneous injection; MK-677 is taken by mouth. That is the difference most people actually feel: Ipamorelin means reconstituting a vial and injecting; MK-677 does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

The kinetics are roughly 12× apart — 24 h for MK-677 against 2 h for Ipamorelin — and yet both are dosed once daily. That schedule is convention rather than clearance, which is worth knowing before you assume the two behave the same way between doses.

Committed time differs: Ipamorelin runs 12 weeks, MK-677 runs 16 weeks.

Ipamorelin is rated beginner here and MK-677 intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.